Multiple Myeloma Articles | Page 3

BCMA Antibody-Drug Conjugate Reaches 60% Response in Myeloma
The B-cell maturation antigen antibody-drug conjugate GSK2857916 induced an overall response rate of 60% in heavily pretreated patients with multiple myeloma.
Elotuzumab/Lenalidomide Maintenance Deepens Responses After Transplant in Myeloma
Maintenance therapy with elotuzumab (Empliciti) and lenalidomide (Revlimid) after autologous stem cell transplant improves the quality of response achieved with induction therapy in patients with multiple myeloma.
Daratumumab Demonstrates Single-Agent Activity in Smoldering Myeloma
Daratumumab (Darzalex) displayed single-agent activity in intermediate- and high-risk smoldering multiple myeloma, according to results from the phase II CENTAURUS study.
Daratumumab Plus VMP New Standard of Care for Some Newly Diagnosed Myeloma Patients
The addition of daratumumab to bortezomib, melphalan, and prednisone (VMP) reduced the risk of progression or death by 50% compared with VMP alone for transplant-ineligible patients with newly diagnosed multiple myeloma.
Curative Approach Improves Responses in Patients With Smoldering Multiple Myeloma
A novel approach demonstrated durable responses in the treatment of patients with smoldering multiple myeloma, according to results from a single-arm, phase II trial.
BCMA-Directed bb2121 Highly Effective for Myeloma
Treatment with the BCMA-directed CAR T-cell therapy bb2121 induced complete remissions for 56% of patients with relapsed/refractory multiple myeloma. 
Oncology Experts Highlight Practice-Changing Abstracts at ASH 2017
Key opinion leaders share their insight on the pivotal and highly anticipated abstracts across hematologic malignancies, including lymphoma, leukemia, and multiple myeloma, ahead of 2017 ASH Annual Meeting and exactly how these findings could be implemented in and affect clinical practice.
FDA Lifts Holds on 2 Nivolumab Myeloma Trials
The FDA has lifted partial clinical holds placed on the phase I CheckMate-039 and phase II CA204142 trials exploring nivolumab-based regimens in patients with relapsed/refractory multiple myeloma.
Triplet Therapy With Selinexor Tested in Myeloma
Selinexor, a novel drug that targets a tumor-suppressor “cargo” protein mechanism, is being investigated in patients with relapsed/refractory multiple myeloma who have received 1 to 3 prior treatment regimens.
Sameh Mikhail, MD, discusses the promise of daratumumab, as well as the potential of medical marijuana to curb the adverse events seen with potent anticancer drugs.
Publication Bottom Border
Border Publication